budesonide glycopyrrolate formoterol Breztri Aerosphere
Selected indexed studies
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. (Am J Respir Crit Care Med, 2021) [PMID:33252985]
- Drugs for COPD. (Med Lett Drugs Ther, 2020) [PMID:32960872]
- Budesonide/Glycopyrronium/Formoterol: A Review in COPD. (Drugs, 2021) [PMID:34342835]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Budesonide/Glycopyrronium/Formoterol: A Review in COPD. (2021) pubmed
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. (2021) pubmed
- Drugs for COPD. (2020) pubmed
- Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. (2026) pubmed
- [Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®]. (2022) pubmed
- Drugs for COPD. (2024) pubmed
- Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study. (2025) pubmed
- Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. (2021) pubmed
- Environmentally sustainable UV spectrophotometric-chemometric approach for simultaneous determination of budesonide, glycopyrrolate, and formoterol. (2026) pubmed
- A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease. (2021) pubmed